Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) and Tauriga Sciences (OTCMKTS:TAUG – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.
Valuation & Earnings
This table compares Mind Medicine (MindMed) and Tauriga Sciences”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Mind Medicine (MindMed) | N/A | N/A | -$95.73 million | ($2.26) | -2.76 |
Tauriga Sciences | N/A | N/A | N/A | N/A | N/A |
Insider & Institutional Ownership
Profitability
This table compares Mind Medicine (MindMed) and Tauriga Sciences’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Mind Medicine (MindMed) | N/A | -47.56% | -35.55% |
Tauriga Sciences | N/A | N/A | N/A |
Analyst Recommendations
This is a summary of recent ratings and price targets for Mind Medicine (MindMed) and Tauriga Sciences, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Mind Medicine (MindMed) | 0 | 0 | 10 | 3 | 3.23 |
Tauriga Sciences | 0 | 0 | 0 | 0 | 0.00 |
Mind Medicine (MindMed) currently has a consensus price target of $26.33, indicating a potential upside of 322.69%. Given Mind Medicine (MindMed)’s stronger consensus rating and higher possible upside, research analysts clearly believe Mind Medicine (MindMed) is more favorable than Tauriga Sciences.
Summary
Mind Medicine (MindMed) beats Tauriga Sciences on 5 of the 8 factors compared between the two stocks.
About Mind Medicine (MindMed)
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
About Tauriga Sciences
Tauriga Sciences, Inc. produces and sells cannabidiol infused chewing gum under the Tauri-Gum brand name. It also develops anti-nausea products; and skin care products include CBD facemasks; CBD daily moisturizer; CBD anti-wrinkle dream, hand, and foot cream with hemp seed oil; CBD massage and body oil; CBD body revive roll-on; CBD transdermal patch; and CBD body spray. In addition, the company offers rainbow deluxe sampler pack, CBD non-GMO dietary supplements, and CBD scented bath bombs. It sells its products through e-commerce, distributors, and wholesale channels. The company has a collaboration agreement with Aegea Biotechnologies, Inc. to develop a rapid, multiplexed COVID-19 (novel coronavirus) test. Tauriga Sciences, Inc. was founded in 2001 and is headquartered in Wappingers Falls, New York.
Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.